Drug Use-Results Survey of OPDIVO (Gastric Cancer)

Drug Use-Results Survey of OPDIVO [unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224011

Enrollment

500

Registered

2018-07-26

Start date

2018-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

investigational material(s) Generic name etc : Opdivo Intravenous Infusion 20 mg, Opdivo Intravenous Infusion 100 mg INN of investigational material : nivolumab Therapeutic category code : 429 Other a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy for whom OPDIVO is administered

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety items : Occurrence of adverse drug reactions/infections, factors considered to influence the safety Efficacy items : Comprehensive improvement, factors considered to influence the efficacy	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026